Open AccessMiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2
Author(s) -
Liang Wen,
Fangzhi Cheng,
Yanyan Zhou,
Yin Chen
Publication year - 2015
Publication title -
the saudi journal of gastroenterology/saudi journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.608
H-Index - 32
eISSN - 1998-4049
pISSN - 1319-3767
DOI - 10.4103/1319-3767.166206
Subject(s) - cisplatin , gene knockdown , cancer research , neuroblastoma ras viral oncogene homolog , propidium iodide , flow cytometry , apoptosis , microrna , luciferase , annexin , oncogene , cancer cell , medicine , cancer , microbiology and biotechnology , chemistry , biology , cell culture , cell cycle , chemotherapy , transfection , kras , gene , programmed cell death , biochemistry , genetics , colorectal cancer
MiR-26a has been identified as a tumor suppressor in various tumors, but the relationship between miR-26a and the sensitivity of gastric cancer to chemotherapies has not been established. The present study was performed to investigate the effect of miR-26a on drug sensitivity in gastric cancer (GC).